Drug resistance is a clinically relevant problem in the treatment of acute myeloid leukaemia (AML). We have previously reported a relationship between single nucleotide polymorphisms (SNPs) of ABCB1, encoding the multi-drug transporter P-glycoprotein, and overall survival (OS) in normal karyotype (NK)-AML. Here we extended this material, enabling subgroup analysis based on FLT3 and NPM1 status, to further elucidate the influence of ABCB1 SNPs. De novo NK-AML patients (n = 201) were analysed for 1199G>A, 1236C>T, 2677G>T/A and 3435C>T, and correlations to outcome were investigated. FLT3 wild-type 1236C/C patients have significantly shorter OS compared to patients carrying the variant allele; medians 20 vs. 49 months, respectively, P = 0·017. There was also an inferior outcome in FLT3 wild-type 2677G/G patients compared to patients carrying the variant allele, median OS 20 vs. 35 months, respectively, P = 0·039. This was confirmed in Cox regression analysis. Our results indicate that ABCB1 1236C>T and 2677G>T may be used as prognostic markers to distinguish relatively high risk patients in the intermediate risk FLT3 wild-type group, which may contribute to future individualizing of treatment strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjh.13097 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
Blood
January 2025
Massachusetts General Hospital, Boston, Massachusetts, United States.
BMT CTN 1506 ("MORPHO"; NCT02997202) was a randomized phase 3 study of gilteritinib compared to placebo as maintenance therapy after hematopoietic stem cell transplantation (HCT) for patients with FLT3-ITD-mutated acute myeloid leukemia (AML). A key secondary endpoint was to determine the impact on survival of pre- and/or post-HCT measurable residual disease (MRD), as determined using a highly sensitive assay for FLT3-ITD mutations. Generally, gilteritinib maintenance therapy was associated with improved relapse-free survival (RFS) for participants with detectable peri-HCT MRD, whereas no benefit was evident for those lacking detectable MRD.
View Article and Find Full Text PDFThe Role of FLT3-ITD Mutation, PI3K/AKT Pathway, and Leukemia Stem Cells in D3A7 Induction therapy - the Outcomes of Adult Indonesian Patients with Acute Myeloid Leukemia.
Acta Med Acad
August 2024
Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Objective: This cohort study aimed to examine the impact of the FLT3-ITD mutation on the downstream signaling pathway of PI3K/AKT pathway, the percentage of leukemia stem cells, and the survival of patients receiving D3A7 induction therapy.
Method: Bone marrow mononuclear cells were collected from 20 adult AML patients who had completed D3A7 induction therapy at Cipto Mangunkusumo National General Hospital and Dharmais Cancer Hospital. FLT3-ITD gene mutation was examined by the PCR-sequencing method.
The Clinical Impact of NPM1 Mutations and the Effect of Concurrent Mutations in Acute Myeloid Leukemia: Unraveling the Prognostic Significance.
Health Sci Rep
December 2024
Department of Molecular Biology and Biotechnology, Human Genetics Division Atomic Energy Commission Damascus Syria.
Article Synopsis
- Nucleophosmin (NPM1) gene mutations are found in 30%-35% of acute myeloid leukemia (AML) patients, with higher prevalence (50%-60%) among those with a normal karyotype.
- In a study involving 100 newly diagnosed Syrian AML patients, 22% exhibited NPM1 mutations, primarily of type A, and their presence was linked to worse outcomes, such as higher mortality rates and increased bone marrow blast percentages.
- These findings highlight the importance of assessing NPM1 mutations for better prognosis and tailored treatment strategies in AML patients with normal karyotypes.
PRDM16 Induces Methylation of FLT3 to Promote FLT3-ITD Signaling and Leukemia Progression.
Cancer Res
November 2024
1. Department of Hepatobiliary Surgery, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China. 2. Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, Hefei, Anhui, 230001, China. 3. Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei, Anhui, 230001, China., Hefei, Anhui, China.
Internal tandem duplication (ITD) in the FMS-like receptor tyrosine kinase-3 (FLT3) is one of the most frequent mutations in acute myeloid leukemia (AML) and is associated with poor prognosis. FLT3-ITD mutations result in endoplasmic reticulum (ER) retention and constitutive autophosphorylation of FLT3. The PR/SET domain 16 (PRDM16) is highly expressed in FLT3-ITD+ AML patients, suggesting it might play a role in leukemogenesis.
View Article and Find Full Text PDFExploring the Prevalence and Prognostic Impact of Wilms Tumor 1 Exon 7 Mutation Status with Combinations of FLT3-ITD and NPM1 Mutations as Potential Molecular Biomarkers in Acute Myeloid Leukemia Patients with Normal Cytogenetics.
Asian Pac J Cancer Prev
October 2024
Cancer Epidemiology and Biostatistics, Regional Cancer Centre, Thiruvananthapuram, University of Kerala, India.
Article Synopsis
- This study investigates the effects of specific genetic mutations (FLT3-ITD, NPM1, WT1) on the outcomes of patients with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML), finding notable survival differences based on NPM1 mutation status.
- Out of 150 patients analyzed, 12.6% had WT1 mutations, and relationships were identified between mutation presence and certain clinical factors, like LDH and hemoglobin levels; however, correlations with overall survival were not consistently significant.
- The results indicate that assessing NPM1 and FLT3-ITD mutations at diagnosis can help predict patient prognosis in AML; further research with larger groups could provide deeper insights
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!